Pfizer Ltd has posted a consolidated net profit of Rs 75.94 crore for the year ended November 30, 2002 (FY-02) where as the net profit was at Rs 47.49 crore for the year ended November 30, 2001 (FY-01). Total income stood at Rs 602.50 crore in FY-02 whereas the same was Rs 359.14 crore in the FY-01.
The Company has posted a net profit of Rs 33.78 crore for the quarter ended November 30, 2002 where as the net profit was at Rs 11.39 crore for the quarter ended November 30, 2001. Total income stood at Rs 133.19 crore in Q4-02 whereas the same was Rs 100.45 crore in the Q4-01.
The Scheme of Amalgamation of Parke-Davis (India) Limited with Pfizer Limited is approved by the Bombay High Court by its Order passed on February 7, 2003. In view of the approval of Scheme of Amalgamation, which is effective December 1, 2001, the audited figures for the year ended November 30, 2002 includes the figures of the erstwhile Parke-Davis (India) Limited.
The figures for the following periods relate only to Pfizer Limited and do not include figures of erstwhile Parke-Davis (India) Limited:
Figures for the last quarter ended November 30, 2002.
Figures for the quarter ended November 30, 2001.
Audited Figures for the year ended November 30, 2001.
In view of the above, the audited figures for the year ended November 30, 2002 are not comparable with the figures for the previous periods.
The Board of Directors of Pfizer Ltd has recommended a Dividend @75% ie Rs 7.50 per share. This includes a one time special dividend of Rs 2.50 per share (25%) consequent to exceptional income received relating to termination of Trademark License of Dumex & Protinex. This proposed dividend includes the dividend to be paid on pari passu basis on the equity shares to be allotted to those shareholders of Parke Davis whose names appear of the Register of Members on the record date ie March 14, 2003.